Claims for Patent: 9,907,775

Summary for Patent: 9,907,775

Title:	Compositions and methods of use of phorbol esters
Abstract:	Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of cytopathic diseases. Cytopathic diseases may be caused by a variety means such as viral infections like HIV and AIDS in a mammalian subject. The methods and compositions of the invention are effective for inhibiting de novo HIV infection, upregulating viral expression from latent provirus, inhibiting HIV-induced cytopathic effects, down regulating the HIV receptor, increasing ThI cytokine expression, and decreasing Th2 cytokine expression. Additional compositions and methods are provided which employ a phorbol ester or derivative compound in combination with at least one additional agent such as those used in HAART protocols or therapeutic agents used to treat opportunistic infections due to HIV in mammalian subjects.
Inventor(s):	Han; Zheng Tao (Eugene, OR), Chang; Richard L. (Laguna Woods, CA)
Assignee:	BIOSUCCESS BIOTECH COMPANY (Los Angeles, CA)
Application Number:	15/429,311
Patent Claims:	1. A method for treating HIV infection or disease in a mammalian subject comprising administering an effective amount of a phorbol ester of Formula I or a pharmaceutically-acceptable salt thereof to said mammalian subject ##STR00016## wherein R.sub.1 and R.sub.2 are selected from the group consisting of hydrogen, ##STR00017## and R3 is selected from hydrogen or ##STR00018## and at least at least one secondary or anti-retroviral or other adjunctive therapeutic agent. 2. A method for treating one or more symptoms or conditions of HIV infection or AIDS in a mammalian subject comprising administering an effective amount of a phorbol ester of Formula I or a pharmaceutically-acceptable salt thereof to said mammalian subject ##STR00019## wherein R.sub.1 and R.sub.2 are selected from the group consisting of hydrogen, ##STR00020## and R.sub.3 is selected from hydrogen or ##STR00021## and at least at least one secondary or anti-retroviral or other adjunctive therapeutic agent. 3. A method for controlling HIV infection in a mammalian subject with AIDS comprising administering an effective amount of a phorbol ester of Formula I or a pharmaceutically-acceptable salt thereof to said mammalian subject ##STR00022## wherein R.sub.1 and R.sub.2 are selected from the group consisting of hydrogen ##STR00023## and R.sub.3 is selected from hydrogen or ##STR00024## and at least at least one secondary or anti-retroviral or other adjunctive therapeutic agent. 4. A method for activating latent reservoirs of HIV comprising administering an effective amount of a phorbol ester of Formula I or a pharmaceutically-acceptable salt thereof to a mammalian subject in need thereof, ##STR00025## wherein R.sub.1 and R.sub.2 are selected from the group consisting of hydrogen, ##STR00026## and R.sub.3 is selected from hydrogen or ##STR00027## and at least at least one secondary or anti-retroviral or other adjunctive therapeutic agent. 5. A method of increasing the expression of Th1 cytokines comprising administering an effective amount of a phorbol ester of Formula I or a pharmaceutically-acceptable salt thereof to a mammalian subject in need thereof, ##STR00028## wherein R.sub.1 and R.sub.2 are selected from the group consisting of hydrogen, ##STR00029## and R.sub.3 is selected from hydrogen or ##STR00030## and at least at least one secondary or anti-retroviral or other adjunctive therapeutic agent. 6. A method for treating HIV infection or disease in a mammalian subject comprising administering between about 10 and 1500 .mu.g of a phorbol ester of Formula I or a pharmaceutically-acceptable salt thereof to said mammalian subject ##STR00031## wherein R.sub.1 and R.sub.2 are selected from the group consisting of hydrogen, ##STR00032## and R.sub.3 is selected from hydrogen or ##STR00033## 7. A method for treating one or more symptoms or conditions of HIV infection or AIDS in a mammalian subject comprising administering between about 10 and 1500 .mu.g of a phorbol ester of Formula I or a pharmaceutically-acceptable salt thereof to said mammalian subject ##STR00034## wherein R.sub.1 and R.sub.2 are selected from the group consisting of hydrogen, ##STR00035## and R.sub.3 is selected from hydrogen or ##STR00036## 8. A method for controlling HIV infection in a mammalian subject with AIDS comprising administering between about 10 and 1500 .mu.g of a phorbol ester of Formula I or a pharmaceutically-acceptable salt thereof to said mammalian subject ##STR00037## wherein R.sub.1 and R.sub.2 are selected from the group consisting of hydrogen, ##STR00038## and R.sub.3 is selected from hydrogen or ##STR00039## 9. A method for activating latent reservoirs of HIV comprising administering between about 10 and 1500 .mu.g of a phorbol ester of Formula I or a pharmaceutically-acceptable salt thereof to a mammalian subject in need thereof, ##STR00040## wherein R.sub.1 and R.sub.2 are selected from the group consisting of hydrogen, ##STR00041## and R.sub.3 is selected from hydrogen or ##STR00042## 10. A method of increasing the expression of Th1 cytokines comprising administering between about 10 and 1500 .mu.g of a phorbol ester of Formula I or a pharmaceutically-acceptable salt thereof to a mammalian subject in need thereof, ##STR00043## wherein R.sub.1 and R.sub.2 are selected from the group consisting of hydrogen, ##STR00044## and R.sub.3 is selected from hydrogen or ##STR00045## 11. The method according to claim 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, wherein the phorbol ester of Formula I is selected from the group consisting of phorbol 13-butyrate, phorbol 12-decanoate, phorbol 13-decanoate, phorbol 12,13-diacetate, phorbol 13,20-diacetate, phorbol 12,13-dibenzoate, phorbol 12,13-dibutyrate, phorbol 12,13-didecanoate, phorbol 12,13-dihexanoate, phorbol 12,13-dipropionate, phorbol 13-myristate, 12-deoxyphorbol 13-angelate, 12-deoxyphorbol 13-angelate 20-acetate, 12-deoxyphorbol 13-isobutyrate, 12-deoxyphorbol 13-isobutyrate-20-acetate, 12-deoxyphorbol 13-phenylacetate, 12-deoxyphorbol 13-phenylacetate 20-acetate, 12-deoxyphorbol 13-tetradecanoate, phorbol 12-tigliate 13-decanoate, 12-deoxyphorbol 13-acetate, phorbol 12-acetate, phorbol-12-myristate, phorbol-12,13,20-triacetate, and phorbol 13-acetate. 12. The method according to claim 1, 2, 3, 4 or 5, wherein the at least one secondary anti-retroviral or other adjunctive therapeutic agent is administered to said subject simultaneously with, prior to, or after, administration of said phorbol ester. 13. The method according to claim 1, 2, 3, 4 or 5, wherein the at least one secondary anti-retroviral or other adjunctive therapeutic agent is selected from the group consisting of: protease inhibitors, nucleoside reverse transcriptase, non-nucleoside reverse transcriptase inhibitors, combination drugs, entry and fusion inhibitors, acyclovir, adefovir dipivoxil, aldesleukin, amphotericin b, azithromycin, calcium hydroxylapatite, clarithromycin, doxorubicin, dronabinol, entecavir, epoetin alfa, etoposide, fluconazole, ganciclovir, immunoglobulins, interferon alfa-2, isoniazid, itraconazole, megestrol, paclitaxel, peginterferon alfa-2, pentamidine, poly-1-lactic acid, ribavirin, rifabutin, rifampin, somatropin, testosterone, trimetrexate, valganciclovir; integrase inhibitors, microbicides, and IL-2. 14. The method according to claim 1, 2, 3, 4 or 5, wherein said effective amount is between about 10 and 1500 .mu.g of said phorbol ester every other day. 15. The method of claim 14, wherein said effective amount is between about 150 to 500 .mu.g of said phorbol ester every other day. 16. The method according to claim 6, 7, 8, 9, or 10, wherein said phorbol ester is administered every other day. 17. The method of claim 16, wherein said effective amount is between about 150 to 500 .mu.g of said phorbol ester every other day. 18. The method according to claim 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, wherein said effective amount of said phorbol ester is administered once per day. 19. The method of claim 2, wherein the one or more symptoms is selected from the group consisting of oral lesions, fatigue, skin thrush, fever, lack of appetite, diarrhea, apthous ulcers, malabsorbtion, thrombocytopenia, weight loss, anemia, and lymph node enlargement, mycobacterium avium complex, salmonellosis, syphilis, neuroshyphilis, turberculosis, bacillary angiomatosis, aspergillosis, candidiasis, coccidioidomycosis, listeriosis, pelvic inflammatory disease, Burkitt's lymphoma, cryptococcal meningitis, histoplasmosis, Kaposi's sarcoma, lymphoma, systemic non-Hodgkin's lymphoma, primary CNS lymphoma, cryptosporidiosis, isosporiasis, microsporidiosis, pneumocystis carinii pneumonia, toxoplasmosis, cytomegalovirus, hepatitis, herpes simplex, herpes zoster, human papiloma virus, molluscum contagiosum, oral hairy leukoplakia, and progressive multifocal leukoencephalopathy.

Details for Patent 9,907,775

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Eli Lilly And Company	HUMATROPE	somatropin	For Injection	019640	06/23/1987		2027-01-31
Eli Lilly And Company	HUMATROPE	somatropin	For Injection	019640	10/16/1986		2027-01-31
Eli Lilly And Company	HUMATROPE	somatropin	For Injection	019640	02/04/1999		2027-01-31
Emd Serono, Inc.	SAIZEN	somatropin	For Injection	019764	10/08/1996		2027-01-31
Emd Serono, Inc.	SAIZEN	somatropin	For Injection	019764	08/29/2000		2027-01-31
Emd Serono, Inc.	SAIZEN	somatropin	For Injection	019764	01/16/2007		2027-01-31
Ferring Pharmaceuticals Inc.	ZOMACTON	somatropin	For Injection	019774	05/25/1995		2027-01-31